These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 39173844

  • 1. Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants.
    Ford BE, Chachra SS, Alshawi A, Oakley F, Fairclough RJ, Smith DM, Tiniakos D, Agius L.
    Biochem Pharmacol; 2024 Nov; 229():116499. PubMed ID: 39173844
    [Abstract] [Full Text] [Related]

  • 2. The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326.
    Ford BE, Chachra SS, Rodgers K, Moonira T, Al-Oanzi ZH, Anstee QM, Reeves HL, Schattenberg JM, Fairclough RJ, Smith DM, Tiniakos D, Agius L.
    Mol Metab; 2023 Jun; 72():101722. PubMed ID: 37031802
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ, Wilkinson GP, Atkinson AM, Jones HB, Coghlan M, Charles AD, Leighton B.
    Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study.
    Wang K, Shi M, Luk AOY, Kong APS, Ma RCW, Li C, Chen L, Chow E, Chan JCN.
    Cardiovasc Diabetol; 2024 Jun 29; 23(1):228. PubMed ID: 38951793
    [Abstract] [Full Text] [Related]

  • 9. Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD.
    Zhang Z, Ji G, Li M.
    Front Endocrinol (Lausanne); 2023 Jun 29; 14():1247611. PubMed ID: 37711901
    [Abstract] [Full Text] [Related]

  • 10. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population.
    Vaxillaire M, Cavalcanti-Proença C, Dechaume A, Tichet J, Marre M, Balkau B, Froguel P, DESIR Study Group.
    Diabetes; 2008 Aug 29; 57(8):2253-7. PubMed ID: 18556336
    [Abstract] [Full Text] [Related]

  • 11. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
    Ericsson H, Röshammar D, Wollbratt M, Heijer M, Persson M, Ueda S, Leonsson-Zachrisson M, Norjavaara E.
    Int J Clin Pharmacol Ther; 2012 Nov 29; 50(11):765-77. PubMed ID: 22943931
    [Abstract] [Full Text] [Related]

  • 12. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
    Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E.
    Diabetes Obes Metab; 2013 Oct 29; 15(10):923-30. PubMed ID: 23522182
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
    Norjavaara E, Ericsson H, Sjöberg F, Leonsson-Zachrisson M, Sjöstrand M, Morrow LA, Hompesch M.
    J Clin Endocrinol Metab; 2012 Sep 29; 97(9):3319-25. PubMed ID: 22723318
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence.
    Zelent B, Raimondo A, Barrett A, Buettger CW, Chen P, Gloyn AL, Matschinsky FM.
    Biochem J; 2014 May 01; 459(3):551-64. PubMed ID: 24568320
    [Abstract] [Full Text] [Related]

  • 16. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
    Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M.
    Diabetes Obes Metab; 2014 Nov 01; 16(11):1096-101. PubMed ID: 24909093
    [Abstract] [Full Text] [Related]

  • 17. Current Insight on the Role of Glucokinase and Glucokinase Regulatory Protein in Diabetes.
    Paliwal A, Paliwal V, Jain S, Paliwal S, Sharma S.
    Mini Rev Med Chem; 2024 Nov 01; 24(7):674-688. PubMed ID: 37612862
    [Abstract] [Full Text] [Related]

  • 18. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
    Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E.
    Diabetes Obes Metab; 2013 Aug 01; 15(8):750-9. PubMed ID: 23464532
    [Abstract] [Full Text] [Related]

  • 19. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
    Al-Oanzi ZH, Fountana S, Moonira T, Tudhope SJ, Petrie JL, Alshawi A, Patman G, Arden C, Reeves HL, Agius L.
    Diabetes Obes Metab; 2017 Aug 01; 19(8):1078-1087. PubMed ID: 28206714
    [Abstract] [Full Text] [Related]

  • 20. Lessons from glucokinase activators: the problem of declining efficacy.
    Agius L.
    Expert Opin Ther Pat; 2014 Nov 01; 24(11):1155-9. PubMed ID: 25266490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.